МС №4 3013 Неврология/Ревматология 4. Депрессия при болезни паркинсона как ведущий фактор ухудшения качества жизни пациентов: патофизиология, диагностика, терапия М.Р. Нодель, к.м.н., Клиника нервных болезней Первого МГМУ им. И.М. Сеченова Литература 1. Яхно Н.Н. Невро-психиатрия. Место неврологов. X Всероссийский съезд неврологов с международным участием. Материалы съезда./ Н. Новгород. 2012. С.698. 2. Яхно Н.Н. Захаров В.В., Нодель М.Р. Когнитивные и другие нервно-психические нарушения болезни Паркинсона. // В кн. Болезни движений: медицинские и социальные аспекты. /под. ред. Е.И. Гусева, А.Б. Гехт. М. 2010. С.95–97. 3. Нодель М.Р., Яхно Н.Н. Нервно-психические нарушения болезни Паркинсона. //Неврология. Нейропсихиатрия. Психосоматика. 2009. №2. C.3–8. 4. Нодель М.Р. Недвигательные нарушения болезни Паркинсона. //Доктор.Ру. Неврология. 2009. №4. C.12– 16. 5. Левин О.С. Болезнь Паркинсона как нейропсихиатрическое заболевание. //Руководство для врачей по материалам II Национального конгресса по болезни Паркинсона и расстройствам движений (под ред. С.Н. Иллариошкина, О.С. Левина). М. 2011. С.99–104. 6. М.Р. Нодель. Клинические особенности и лечение недвигательных нарушений болезни Паркинсона.// Медицинский совет. -2012.-N 4.-С.30-36. 7. D.Aarsland, Marsh L., A.Schrag . Neuropsychiatric symptoms in Parkinsons Disease. //Mov.Dis.-2009Vol.24(15).-P.2175-86. 8. OSullivan S.S., Williams D.R., Gallarher D.A., et,.al. Non motor symptoms as presenting complaints in Parkinsons disease: a clinicopathological study. //Mov.Dis.-2008-Vol.23-P.101-106. 9.Shrag A., Jahanshahi M., Quinn N.P. What contributes to quality life in patients with Parkinsons disease?//J.Neurol.Neurosurg.Neuropsych.-2000.-Vol.69.-P.308-312. 10.Scaravilli T., Gasparoli E., Rinaldi F. et.al. Health related quality of life in Parkinsons disease. // J.Nourol.Neurosurg.Psychiat.-2003.-74 (2)-P.163-169. 11.Mc Kinlay A., Grace R.C., Dalrymple-Alford J.C., et.al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinsons disease. //Park. and Relat. disord.-2008.-Vol.14.-P.37-42 12.Cole S. A., Woodard J. L. , Juncos J. L. , et. al. Depression and disability in Parkinsons disease. // J. Neuropsychiatry Clin. Neurosci. -1996. - Vol. 8. - P. 20-25. 13.Shrag A., Jahanshahi M., Quinn N.P. What contributes to depression in Parkinsons disease?// Psychol.Med.2001.-Vol.31.-P.65-73. 14.S.E.Starkstein, Preziosi T.J., Robinson R.G. Sleep disorders, pain and Parkinsons disease depression in Parkinsons disease. //Eur. Neurol.-1991.-Vol.31(6).-P.352-355. 15.Norman S., Troster A.I., Fields J.A., et.al. Effects of depression and Parkinsons disease on cognitive functioning. . // J.Neuropsychiatr.Clin. Neurosci.-2002.-Vol.14(1).-P.31-36. 16.М.Р. Нодель. Депрессия при болезни Паркинсона. //Неврология. Нейропсихиатрия.Психосоматика.-2010.-N4.- C.11-17. 17.Dooneief G., Mirabello E., Bell K., et.al. An estimate of the incidence of depression in idiopathic Parkinsons disease. //Arch.Neurol.-1992.-Vol.49(3).-P.305-307. 18.Lemke M.R. Depressive symptoms in Parkinsons disease. //Eur. J.of Neurol.-2008.-Vol.15(Suppl.1).-P.21-25. 19.Gotham A. M., Brown R. C. , Marsden C. D. Depression in Parkinsons disease: a quantitative and qualitative analysis in Parkinsons disease. // J. Neuropsychiatry Clin. Neurosci. -1996. - Vol. 8. - P. 20-25. 20.Mayberg H.S., Starkstein S.E., Sadzot B., et.al. Selective hypometaboloism in the inferior frontal lobe in depressed patients with Parkinsons Disease. //Ann.Neurol.-1990.-Vol.28(1)-P.57-64. 21.Matsiu H., Nishinaka K., Oda M., et.al. Depression in Parkinsons disease:diffusion tensor imaging study. //J.Neurol.-2007.-Vol.254.-P.1170-1173. 22. Chaudhuri K.R., Schapira A. H.V. Non-motor symptoms of Parkinsons disease: dopaminergic pathophysiology 23. R.Mayeux, Y.Stern, I.Cote , J.B. Williams. Altered serotonin metabolism in depressed patients with Parkinsons Disease. //Neurol.-1984.-Vol.34(5).-P.642-646. 24. M.Yamomoto. Depression in Parkinsons Disease : its prevalence, diagnosis, and neurochemical background. //J.Neurol.-2001.-Vol.248 (Suppl 25. P.G.Frisina, V.Haroutunian, L.S.Libow. The neuropatological basis for depression in Parkinsons Disease. //Park. and Relat.Dis.-2009.-Vol.15.-P.144-148. 26. Remy P., M.Doder, A.Lees, et.al. Depression in Parkinsons Disease: loss of dopamine and noradrenaline innervation in the limbic system. //Brain.-2005.-Vol.128.-P.1314-1322. 27. M.Guttman, M.Torti, J.Warsh et.al. Are brain serotonin transporter levels decreased in depressed patients with Parkinsons Disease? //J.Neurol.Sci-2006.-Vol.248-P.299. 28.Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotoninergic regulation of dopamine neurotransmission. // Pharmacol. Ther.-2007.-Vol.113-P.296-320. 29.F.Fang, Q.Xu, Y.Park, X.Huang, et.al. Depression and the subsequent risk of Parkinsons disease in the NINAARP Diet and Health Study. //Mov.Dis.-2010-Vol.25.-N9.-P.1157-1162. 30.Braak H., Del Tredici K., Rub U., et. al. Staging of brain pathology related to sporadic Parkinsons disease. //Neurology Aging - 2003.-Vol.24.-P.197-210. 31.Santamaria J. , Tolosa E. , Valles A. Parkinsons disease with depression: a possible subgroup of idiopathic parkinsonism. //Neurology. -1986. - Vol. 36. - P. 1130-1133. 32.A.F.Leentjens, R.Lousberg, F.R.Verhey. Markers for depression in Parkinsons Disease. //Acta Psych.Scand.2002.-Vol.106(3)-P.196-201. 33.Cummings J. L. Depression and Parkinsons disease: a review. // Am. J. Psychiatry-1992. - Vol. 149. - P. 443454. 34.E.Tanberg, J.P.Larsen, D.Aarsland et.al. Risk factors for depression in Parkinsons Disease. //Arch. Neurol.1997.-Vol.54(5).-P.625-630. 35.A.Rojo , M.Agullar , M.T. Garolera , et.al. Depression and Parkinsons disease: clinical correlates and outcome. //Park. Relat Dis.- 2003.-Vol.10(1).-P.23-28. 36. Cole S.A., Woodard J.L., Juncos J.L., et.al. Depression and disability in Parkinsons disease. //J.Neuropsychiatr.Clin. Neurosci-1996.-Vol.8(1).-P.20-25. 37. C.Becker, G.P.Brobert, S.Johansson et.al. Risk of incident depression in patients with Parkinsons disease in the UK. //Eur.J.of Neurol.-2011.-Vol.18.-P.448-453. 38. A.Althaus, O.A.Becker, A.Spottke, et.al. Frequency and treatment of depressive symptoms in a Parkinsons Disease registry. //Park. and Relat. disord.-2008.-Vol.14.-P.626-632 39.Y.Cheng, C.Liu, C.Mao et.al. Social support plays a role in depression in Parkinsons disease: a cross-section study in a Chinese cohort. //Park. аnd Related Dis.-2008.-Vol.14.-P.43-45. 40.Янакаева Т. А. Сравнительный анализ когнитивных и аффективных расстройств при дисциркуляторной энцефалопатии, болезни Паркинсона и болезни Альцгеймера. Диссертация …канд. мед. наук. – М., 1999. 41.E.Starkstein, Petracca G., Chemerinski E., et.al. Depression in classic versus akinetic-rigid Parkinsons disease. //J.Neur. Ment.Dis.-1998.-Vol.13(1).P.-29-33. 42. F.Liebermann. Depression in Parkinsons Disease- a review. //Acta Neurol.Scand.-2006.-Vol.113-P.1-8. 43.Lemke M.R. Depressive symptoms in Parkinsons disease. //Eur.J.of Neurol.-2008.-Vol.15(Suppl.1).-P.21-25. 44. American Psychiatric Association. Diagnostic and Statistical Manual of mental Disorders, 4-th ed. Washington, ВС:APA Press 2000. 45. J.Reiff, N.Schmidt, B.Riebe, et.al. Subthreshold depression in Parkinsons disease. //Mov.Dis.-2011-Vol.26N9.-P.1741-1744. 46.S.E.Starkstein , M.Merello, R.Jorge , et.al. A validity study of depressive syndromes in Parkinsons disease. // Mov.Dis.-2008-Vol.23-P.538-546. 47.T.Inoue, M.Kitagawa, T.Tanaka, et.al. Depression and major depressive disorder in patients with Parkinsons disease. // Mov.Dis.-2010-Vol.25-N1-P.44-49. 48.Barone P., Antonini A., Colosimo C., et.al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson disease. //Mov.Dis.-2009.-Jun 9.-P.215-216. 49. Shrag A., Barone P., Brown R.G. et.al. Depression rating scales in Parkinson disease: critique and recommendations. //Mov.Dis.-2007.-Vol.22.-P.1077-1192. 50.Dujardin K., Sockeel P., Devos D., et.al. Characteristic of apathy in Parkinsons disease. // Mov.Dis.-2007.Vol.22.-P.778-784. 51. М.Р. Нодель. Утомляемость при болезни Паркинсона и ее коррекция агонистом дофаминовых рецепторов прамипексолом //Неврология. Нейропсихиатрия.Психосоматика.-2011.-N 4.- C.22-26. 52.Barone P et al. Depression and antidepressant use in Parkinson’s disease: Results from the PRODEST-PD study. Abstract P1122 poster presented at 11th Congress of EFNS, Brussels, 26 Aug 2007. 53.Weintraub D., Morales K.H., Moberg P.J., et.al. Antidepressant studies in Parkinsons disease: a review and meta-analysis. // Mov.Dis.-2005.-Vol.20.-P.1161-1169. 54. Miyasaki J.M., Shannon K., Voon V., et.al. Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinsons disease (an evidence-based review):report of the Quality Standards Subcommittee of the American Academy of Neurology. //Neurol.-2006.-Vol.66.-P.996-1002. 55.Devos D., Dujardin K., Poirot I., et.al. Comparison of desipramine and citalopram treatments with depression in Parkinsons disease: a double-blind placebo-controlled study. //Mov.Dis.-2008.-Vol.23.-P.850-7. 56. I.H.Richard, M.P.McDermott, R.Kurlan et.al. A randomized, double –blind, placebo-controlled trial of antidepressants in Parkinsons disease. //Neurol.-2012-Vol.11-N9.-P.26-34. 57. Menza M., Dobkin R.D., Marin H., et.al. A controlled trial of antidepressants in patients with Parkinsons disease and depression. //Neurol.-2009.-Vol.72.-P.886-92 58. Mann J. J., Kapur S. A dopaminergic hypothesis of major depression. // Clin. Neuropharmacol. -1996. -Vol. 18(suppl. 1). -P. 57-65. 59.Barbeu A. L. L-Dopa therapy in Parkinson disease: a critical review of nine years experience. // J. Can. Med. Assoc. -1969. -Vol. 101. -P. 791-800. 60. Нодель М.Р., Артемьев Д.В., Яхно Н.Н.. Эффективность дофаминового агониста Мирапекса при болезни Паркинсона. // Неврологический журнал. - 1999. – N6. - С. 45-49. 61. Левин О.С., Федорова Н.В., Смоленцева И.Г. Применение агонистов дофаминовых рецепторов при болезни Паркинсона.//Неврологический журнал- 2002. -№1. С.41-45. 62. Lemke M.P., Brecht H.M., Koester J.K., et.al. Anhedonia, depression, and motor functioning in Parkinsons disease during treatment with Pramipexole. //J.Neuropsych.Clin.Neurosci-2005.-Vol.17.-P.2.-P.214-220. 63. Barone P., Poewe W., Tolosa E., et.al. Efficacy of double-blind, placebo-controlled pramipexole against depression in Parkinsons disease. Abstracts of the Movement Disorders Societys Thirteenth International Congress of Parkinson's disease and movement disorders. June 7-11-2009-Suppl.1 –P.291. 4.Schoenfeld M.A., Pantelie C.M., B. Schwartz . Clinical criteria for the switch of treatment strategies in Parkinson’s disease. //Clinical Neurol. and Neurosurg. -2003.-Vol. 105.-P.241-244.